Longer Lasting Version of Schizophrenia Drug Approved

Article

The US Food and Drug Administration today approved 3-month paliperidone palmitate (Invega Trinza/Janssen) a longer-lasting version of Janssen's paliperidone palmitate product marketed as Invega Sustenna, a treatment that works for only 1 month per injection.

Adult patients with schizophrenia will soon have access to an injectable medication that is meant to be given only 4 times a year.

The US Food and Drug Administration today approved 3-month paliperidone palmitate (Invega Trinza/Janssen) a longer-lasting version of Janssen’s paliperidone palmitate product marketed as Invega Sustenna, a treatment that works for only 1 month per injection.

The company expects the newer drug to be available in mid-June, 2015.

The results of a long-term maintenance trial in which 93% of patients treated with the 3-month paliperidone palmitate got significant relief from symptoms were published in March in JAMA Psychiatry.

The longer lasting version uses a patented technology which enables solubility of poorly water-soluble compounds.

The FDA evaluated the trial results under a priority review designation granted in January 2015, just three months afterJanssen initially submitted its new drug application for the product.

Before starting Invega Trinza, patients must be adequately treated with Invega Sustenna for at least 4 months.

“With a dosing interval that can be measured in seasons, not days, people living with schizophrenia and their treatment teams can focus on recovery goals beyond short-term symptom control,” said Invega Trinza trial investigator Joseph Kwentus, MD, in a Janssen news release. “Recovery looks different for everyone, and the long-term symptom control offered by Invega Trinza can help patients work toward their own personal goals.”

The FDA was satisfied that the longer-lasting drug had the same safety profile as the 1-month version.

In its release, Janssen quoted a mental health advocate, Paul Gionfriddo. “As both an advocate and a parent of an adult son with schizophrenia, I can attest to the importance of novel therapies that enable our loved ones to spend more time focusing on their recovery and less time worrying about taking medications,” he said.

Related Videos
Depression Screening: Challenges and Solutions at the Primary Care Level
HCPLive Five at APA 2024 | Image Credit: HCPLive
John M. Oldham, MD: A History of Personality Disorder Pathology
Franklin King, MD: Psychedelic Therapy History, Advances, and Hurdles
Robert Weinrieb, MD: Psychiatry-Hepatology Approach for Alcohol-Related Liver Disease
Etienne Sibille, PhD: Innovations in Cognitive Pathology
Katharine Phillips, MD: Various Treatments for Obsessive-Compulsive Disorders
Manish Jha, MD: Treatment Options for Treatment-Resistant Depression
Katharine Phillips, MD: Differences Between OCD, Body Dysmorphic Disorder
© 2024 MJH Life Sciences

All rights reserved.